Hypoxic/Ischemic Inflammation, MicroRNAs and δ-Opioid Receptors: Hypoxia/Ischemia-Sensitive Versus-Insensitive Organs

Yimeng Chen¹, Yichen He¹, Shuchen Zhao¹, Xiaozhou He¹, Dong Xue¹* and Ying Xia²*

¹ Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, China, ² Shanghai Key Laboratory of Acupuncture Mechanism and Acupoint Function, Fudan University, Shanghai, China

Hypoxia and ischemia cause inflammatory injury and critically participate in the pathogenesis of various diseases in various organs. However, the protective strategies against hypoxic and ischemic insults are very limited in clinical settings up to date. It is of utmost importance to improve our understanding of hypoxic/ischemic (H/I) inflammation and find novel therapies for better prevention/treatment of H/I injury. Recent studies provide strong evidence that the expression of microRNAs (miRNAs), which regulate gene expression and affect H/I inflammation through post-transcriptional mechanisms, are differentially altered in response to H/I stress, while δ-opioid receptors (DOR) play a protective role against H/I insults in different organs, including both H/I-sensitive organs (e.g., brain, kidney, and heart) and H/I-insensitive organs (e.g., liver and muscle). Indeed, many studies have demonstrated the crucial role of the DOR-mediated cyto-protection against H/I injury by several molecular pathways, including NLRP3 inflammasome modulated by miRNAs. In this review, we summarize our recent studies along with those of others worldwide, and compare the effects of DOR on H/I expression of miRNAs in H/I-sensitive and -insensitive organs. The alternation in miRNA expression profiles upon DOR activation and the potential impact on inflammatory injury in different organs under normoxic and hypoxic conditions are discussed at molecular and cellular levels. More in-depth investigations into this field may provide novel clues for new protective strategies against H/I inflammation in different types of organs.

Keywords: MicroRNAs, hypoxic/ischemic inflammation, δ-opioid receptor (DOR), organs' differential responses, NLRP3 inflammasome

INTRODUCTION

MicroRNAs (miRNAs) are a class of 21~25-ribonucleotide single-strand non-coding RNA molecules which is endogenously expressed in eukaryote cells (Guo et al., 2014). It has been well recognized that miRNAs play an important role in the post-transcriptional regulation of genes by targeting mRNA molecules. Through base-pairing with the 3’ untranslated regions (3’UTR), miRNAs modulate direct cleavage and/or translational repression of target mRNAs (Bartel, 2009), thus regulating wide spectrum of processes in physiological and pathological conditions. Their regulatory networks are very complex, partially because miRNA expression varies dramatically in different tissues in response to different cell stimulations.
Hypoxic/ischemic injury is a process in which blood flow cessation and oxygen deprivation occur in the body, organs, or cells. Metabolic waste products are accumulated due to the starvation of oxygen and nutrients, leading to profound tissue dysfunction and damage (Zhao et al., 2018). More specifically, hypoxia is a state of low oxygen supply, resulted from a decrease in partial pressure of oxygen, inadequate oxygen transport, or the inability of the tissues/organs to uptake oxygen from the blood. In contrast, ischemia is defined as inadequate blood flow to the tissues, resulting in the deprivation of oxygen and glucose, as well as other substances in the blood (Chao and Xia, 2010; Yang et al., 2015). In this review, the term of “H/I injury” is used to describe the general influences of hypoxic and/or ischemic insult, because hypoxia and ischemia processes often occur one after another. A wide range of pathophysiological processes have been reported to be associated with H/I injury, including ATP depletion, calcium overload, mitochondrial dysfunction, oxidative stress, and etc. (Eltzschig and Eckle, 2011; Chen et al., 2019). More recently, emerging evidence suggests that H/I inflammation, a quick pathological response to oxygen/blood flow depletion, has a major impact on H/I injury through pro-inflammatory cytokines and their signaling pathways (Chen et al., 2020c; Sikora et al., 2021; Troscher et al., 2021).

Because of energy imbalance, H/I insult induces pro-inflammatory events including microglia activation, cytokines production, and immune cell development via various biological processes such as apoptosis and oxidative reaction (Chen et al., 2020c). Different organs may suffer from H/I inflammation in different ways, thus leading to various H/I-related diseases. H/I neuroinflammation induces brain injury in ischemic stroke and post-stroke epilepsy (Li X. et al., 2020; Troscher et al., 2021; Xue Y. et al., 2021), while H/I inflammation leads to other pathophysiological events in peripheral organs, including heart failure, acute kidney injury, and hepatocellular damages (Nangaku and Eckardt, 2007; Klune and Tsung, 2010; Frohlich et al., 2013; Yang et al., 2015). On the other side, some beneficial reaction may go through the regulation of inflammatory events. For example, long term limb remote ischemic conditioning could decrease blood pressure via inflammation regulation (Gao et al., 2021). Studies have demonstrated the vital roles of miRNAs in the regulation of gene expression under H/I condition, not only in H/I-sensitive organs such as kidney, heart, and brain, but also in the H/I-insensitive organs such as liver and muscle (Nallamshetty et al., 2013; Bertero et al., 2017). H/I inflammation is mediated, at least partially, by the miRNA-induced repression of gene expressions. The alternations of miRNA expression in response to H/I injury differ widely in different organs due to their differential sensitivities to the reduction of oxygen and blood flow. Numerous studies have shown the changes of miRNA expression profiles along with the potential targets and inflammatory pathways upon H/I insult in specific organs (Tables 1, 2). However, few studies have compared the common changes and the differences of miRNA profiles between H/I-sensitive and -insensitive organs.

Opioid receptors belong to the large family of seven-transmembrane G protein-coupled receptors with three major sub-types known as MOR, KOR, and DOR (Xia, 2015). It is well demonstrated that DOR is protective against hypoxic, ischemic, and excitotoxic insults. There exists a differential distribution of DOR in different parts of the brain with a higher density in the cortex, striatum and dorsal root ganglion (Xia, 2015; Tan et al., 2016; Li X. et al., 2020; Gao et al., 2021). DOR is present not only in the nervous system but also in other organs such as the heart, lungs, liver, and gastrointestinal and reproductive tracts (Feng et al., 2012). Our recent studies as well as those of others present strong evidence of the DOR-mediated cytotoxic protection in different organs, including brain, kidney, heart, and liver (Zhang et al., 2000, 2002, 2006; Ma et al., 2005; Chao et al., 2007, 2008, 2009, 2012; Kang et al., 2009; Chao and Xia, 2010; Feng et al., 2011, 2012; He et al., 2013a; Luo et al., 2019). Moreover, there is accumulating evidence that DOR activation can achieve a protective role against H/I injury by modulating miRNA expression in multiple organs (Yang et al., 2012; He et al., 2013b; Zhi et al., 2016, 2017), especially in the process of neuroinflammation (Chen et al., 2020c). It is therefore possible for DOR signaling, directly or indirectly, to protect organs against H/I inflammation by targeting specific miRNA molecules.

In this review, we highlight some of the recent updates about the effects of H/I and DOR activation on miRNA expression in the current literature, along with our recent work in this field. In particular, we intend to summarize and compare differential regulation of miRNA expression in different organs and discuss potential clinical significances in terms of specific DOR treatment against H/I inflammation.

### EFFECTS OF HYPOXIA/ISCHEMIA ON MICRNAs IN HYPOXIA-SENSITIVE ORGANS

#### Kidney

Although blood flow to the kidney accounts for 20% of the cardiac output, the kidney is vulnerable to H/I injury because of the renal vascular anatomy and the high energy consumption of renal tubular epithelial cells (Bracken et al., 2006). H/I-induced inflammatory processes exert a significant role in the development of nephrotic diseases, such as acute kidney injury, glomerulonephritis, and chronic allograft nephropathy (Wang Z. et al., 2020; Nangaku and Eckardt, 2007; Heyman et al., 2008; Chen et al., 2020b). Moreover, the ischemia–reperfusion process during renal transplantation has a profound influence on both short- and long-term recovery outcome of a transplanted kidney (Kosieradzki et al., 2003; Kosieradzki and Rowinski, 2008; Chao et al., 2019). Several studies have suggested that H/I condition, especially a prolonged stress, could strongly influence the miRNA expression profiles in kidneys (Godwin et al., 2010; Shapiro et al., 2011). A number of altered miRNAs have been discovered during H/I kidney injury with identified target genes, which regulate cell inflammatory phenotypes (Table 1). Recent studies in human and rodent models also suggested a crosstalk among different renal cell types after H/I insult. For example, H/I-induced
TABLE 1 | H/I-induced changes of miRNAs in the kidney with defined target genes.

| H/I regulated miRNAs | Species | Target genes | Functions | References |
|----------------------|---------|--------------|-----------|------------|
| Up-regulated by H/I  |         |              |           |            |
| miR-21               | Mouse   | CBS, CSE     | Promote macrophage M1 inflammatory phenotype | Pushpakumar et al., 2021 |
| miR-23a              | Mouse   | A20          | Activate macrophages and promote tubulointerstitial inflammation | Li Z. et al., 2019 |
| miR-24               | Human, mouse | S1PR1, H2A-X, HO-1 | Promote infiltration of inflammatory cells | Lorenzen et al., 2014 |
| miR-155              | Rat     | FoxO3a       | Induce pro-inflammatory cytokines | Wu et al., 2016 |
| miR-214              | Mouse   | mt-Nd6, mt-Nd4I | Disrupt mitochondrial oxidative phosphorylation | Bai et al., 2019 |
| miR-351-5p           | Rat, mouse | MAPK13, SIRT6 | Promote oxidative stress and inflammation | Hu et al., 2018 |
| miR-374b-5p          | Mouse   | Socs1        | Promote M1 macrophage activation and inflammation | Ding et al., 2020 |
| miR-494              | Human, mouse | HtrA3, ATF3 | Enhance renal inflammation | Lan et al., 2012; Gong et al., 2021 |
| miR-1997-3p          | Mouse   | Nucks1       | Modulate inflammation and renal injury | Bellinger et al., 2014 |
| Down-regulated by H/I|         |              |           |            |
| miR-27a              | Rat     | TLR4         | Inhibit inflammation in renal IRI | Wang et al., 2019 |
| miR-194              | Human   | Rheb         | Suppress oxidative stress and inflammation | Shen et al., 2018 |
| miR-195-5p           | Rat     | VEGFA        | Inhibit inflammatory cytokines | Xu et al., 2020a |
| miR-449b-5p          | Rat     | HMGBl, MMP2  | Reduce renal inflammation and apoptosis | Xu et al., 2020b |

TABLE 2 | H/I-induced changes of miRNAs in the heart with defined target genes.

| H/I regulated miRNAs | Species | Target genes | Functions | References |
|----------------------|---------|--------------|-----------|------------|
| Up-regulated by H/I  |         |              |           |            |
| miR-22               | Rat     | Sirt1, PGC1a | Promote mitochondrial oxidative damage | Du et al., 2016 |
| miR-23a              | Rat     | CX43         | Enhance mitophagy and myocardial I/R injury | Wang L. et al., 2021 |
| miR-30c-5p           | Rat     | Bach1, SIRT1 | Regulate cardiac inflammation and NF-κB signaling | Chen et al., 2020a; Sun et al., 2021 |
| miR-181c-5p          | Rat     | PTPN4        | Exacerbate cardiac I/R injury and NF-κB-mediated inflammation | Wang S. et al., 2020 |
| miR-184              | Rat     | FBXO28       | Promote myocardial inflammation and oxidative stress | Zou et al., 2020 |
| miR-199a-214         | Rat     | PPARβ        | Impair mitochondrial fatty acid oxidation | el Azzouzi et al., 2013 |
| miR-327              | Rat     | RPP105       | Enhance inflammation and NF-κB signaling | Yang et al., 2018 |
| miR-346              | Rat     | NFIB         | Promote myocardial inflammation and apoptosis | Yang et al., 2020 |
| miR-361              | Mouse   | PHB1         | Inhibit mitochondrial fission and apoptosis | Wang K. et al., 2015 |
| miR-665              | Rat     | GLP1R        | Promote inflammatory response and impair mitochondrial respiratory chain enzyme activity | Lin et al., 2019 |
| Down-regulated by H/I|         |              |           |            |
| miR-30e              | Rat     | SOX9         | Inhibit myocardial inflammation | Cheng et al., 2021 |
| miR-130a-5p          | Mouse   | HMGBl        | Inhibit inflammatory injury and NF-κB signaling | Li Y. et al., 2021 |
| miR-138              | Human   | PDK1         | Promote mitochondrial respiration and inhibit glycolysis | Zhu et al., 2017 |
| miR-142-3p           | Porcine | IRAK-1       | Attenuate myocardial inflammatory response | Su et al., 2019 |
| miR-147              | Rat     | HIPK2        | Inhibit myocardial inflammation and apoptosis | Wu and Huang, 2020 |
| miR-200a             | Human, mouse | Keap1, β-catenin | Reduce inflammation, ROS production and apoptosis | Sun et al., 2016; Ma Y. et al., 2021 |
| miR-204              | Mouse   | Cot1         | Inhibit myocardial inflammation and oxidative stress | Tan et al., 2020 |
| miR-335              | Rat     | MAP3K2       | Inhibit myocardial inflammation and apoptosis | Wang A. et al., 2021 |
| miR-369              | Rat     | TRPV3        | Reduce hypoxia-induced apoptosis and inflammation | Wang J. et al., 2021 |
| miR-409-5p           | Rat     | USP7         | Inhibit myocardial inflammation | Xue Q. et al., 2021 |
| miR-495              | Mouse   | NRP3         | Inhibit NLRP3 inflammasome signaling | Zhou et al., 2018 |
| miR-499-5p           | Rat     | CnAa, CnAb   | Regulate mitochondrial dynamics | Wang J. et al., 2011 |
| miR-668-3p           | Rat     | SDF-1        | Inhibit inflammation and oxidative stress | Gao et al., 2020 |
| miR-708              | Rat     | HMGBl, ADAM17 | Inhibit pro-inflammatory cytokine and NF-κB signaling | Zhang et al., 2020c; Qu et al., 2021 |
| miR-1278             | Mouse   | IL-22, CXCL14 | Inhibit myocardial inflammation | Liu D. et al., 2021 |

Upregulation of miR-21 and miR-374b-5p could promote renal inflammation by activating M1 macrophage (Ding et al., 2020; Pushpakumar et al., 2021). Renal tubular epithelial cells are usually the initial site of renal injury, with activation of fibroblasts or macrophage occurring later by exosome delivery of specific miRNAs (Tan et al., 2016; Li Z. et al., 2019). Pro-inflammatory cytokine production and tubulointerstitial inflammation induced by miRNAs could eventually cause renal fibrosis (Table 1).
Heart
Heart is a H/I-sensitive organ with active metabolism. H/I-induced myocardial injury is closely associated with cardiac disorders such as myocardial infarction and heart failure (Dirksen et al., 2007; Cassavaugh and Lounsbury, 2011; Frohlich et al., 2013). MicroRNAs have been demonstrated to orchestrate many aspects in the development of heart diseases. Recent research on miRNAs regarding myocardial inflammation has drawn much attention from clinicians and scientists. Under H/I condition, the mismatch between energy production and consumption has profound impacts on mitochondrial function and energy metabolism processes of cardiomyocytes (Table 2). Pro-inflammatory miRNAs such as miR-22, miR-199a-214, miR-361, and miR-665 are elevated (el Azzouzi et al., 2013; Wang K. et al., 2015; Du et al., 2016; Lin et al., 2019), whereas anti-inflammatory miRNAs such as miR-138 and miR-499-5p are reduced (Wang J. et al., 2011; Zhu et al., 2017) to impair normal mitochondrial function in myocardial cells. In addition, abnormal expression of miR-30c-5p, miR-181c-5p, miR-327, miR-130a-5p, and miR-708 upon H/I stimulation could regulate myocardial inflammation through NF-κB signaling (Yang et al., 2018; Chen et al., 2020a; Wang S. et al., 2020; Zhang et al., 2020c; Li Y. et al., 2021; Qu et al., 2021; Sun et al., 2021; Table 2). One of the key inflammatory mediators, NLRP3 inflammasome, may also be a direct target of H/I-sensitive miRNAs. A recent study in rodents identified that miR-495 ameliorated cardiac microvascular endothelial cell injury and inflammatory reaction by suppressing the NLRP3 inflammasome signaling pathway (Zhou et al., 2018).

Brain
Hypoxic and/or ischemic injuries are well-documented entities in the pathogenesis of cerebrovascular diseases such as stroke. The effects of H/I on miRNAs in the brain have been widely investigated in patients as well as animal ischemic models with middle cerebral artery occlusion (MCAO). Our previous reviews have summarized the regulation of brain miRNAs in response to hypoxic and ischemic conditions (Yang et al., 2015) and their impact on neuroinflammatory signaling pathways (Chen et al., 2020c). Many studies have elucidated the possible mechanisms and the potential biological processes of H/I-induced miRNA expression changes. The neuroinflammation processes including NLRP3 signaling, mitochondrial impairment, microglia activation, inflammatory cytokines production, and potentially neurodegeneration (Chen et al., 2017, 2020c). In general, up-regulation of pro-inflammatory miRNAs and down-regulation of anti-inflammatory miRNAs are often observed in H/I brains (Table 3). The majority of dysregulated miRNAs in the brain exposed to H/I insult displayed a reduction of miRNA expression, especially after a long-term exposure. Similarly with other H/I-sensitive organs, cerebral miRNAs can directly influence inflammatory cytokines production by modulating target genes. They can also affect NLRP3 inflammasome and NF-κB signaling to modulate neuroinflammation. Moreover, the abnormal expression of cerebral miRNAs, e.g., miR-186-5p, miR-200b, miR-210, miR-449c-5p, miR-302a-3p, miR-424, miR-665-3p, and let-7c-5p, can alter the activation of microglia, the most important inflammatory cell type in the brain, and then indirectly influence neuroinflammation, neuronal death and neurodegeneration (Table 3).

EFFECTS OF HYPOXIA/ISCHEMIA ON MICRONRNAS IN HYPOXIA-INSENSITIVE ORGANS

Liver
Although liver is regarded as one of the hypoxia-insensitive organs, oxygen is also important for liver function maintenance. The insufficiency or deprivation of oxygen and blood flow in hepatic microenvironment due to respiratory/circulatory disorders leads to hepatocellular damage. Indeed, hypoxia activates multiple hypoxia mediators and in turn accelerate or antagonize hepatic damage (Klune and Tsung, 2010; Lu et al., 2016), such as fatty liver disease (Suzuki et al., 2014), hepatocellular carcinoma (HCC) (Liu et al., 2015), and liver-stage malaria (Ng et al., 2014).

Multiple studies have illustrated the H/I injury-induced miRNA changes in liver inflammation, hepatocellular oxidative stress and apoptosis. Meanwhile, altered miRNAs are closely associated with hypoxia-induced HCC pathogenesis by modulating HCC cell angiogenesis, viability and metastasis (Table 4). For example, the hypoxia-sensitive miR-210, which is regarded as the master orchestrator miRNA to H/I insults, is significantly up-regulated in the liver. It mediates hypoxia-induced liver inflammation and HCC cell metastasis through targeting VMP1 (Yang et al., 2011; Song et al., 2014). In addition, hypoxia elevated miR-370 expression and thus promoted inflammation and hepatic histological damage by targeting TGFBR2 (Li et al., 2015). In contrast, cyto-protective miRNAs including miR-24-3p, miR-140-5p, miR-142-3p, miR-146a, and miR-148a were down-regulated under H/I condition, and thus impaired liver function by elevating pro-inflammatory responses (Table 4).

Muscle
In comparison to other organs, muscles are relatively tolerant to hypoxic and ischemic stress. Like other H/I-sensitive organs, however, H/I-stimulated muscles also regulate several molecular pathways to better adapt to hypoxic/ischemic environments (Zhu et al., 2022). Recent studies have been devoted to underpinning the mechanisms and pathways of miRNA alternations upon ischemia–reperfusion injury, including macrophage polarization, leukocyte infiltration, and pro-inflammatory cytokine production in ischemic muscle (Table 4). It is reported that miR-93 inhibits IRF9 and induces M2-like polarization in ischemic muscles to enhance angiogenesis, arteriogenesis, and perfusion recovery in peripheral artery disease (Ganta et al., 2017). In in vitro studies, pulmonary artery smooth muscle cells (PASMCs) have been used to investigate H/I-induced muscle miRNA alternations. An H/I down-regulation of miR-98 was observed to modulate inflammation and PASMC...
### TABLE 3 | H/I-induced changes of miRNAs in the brain with defined target genes.

| H/I regulated miRNAs | Species | Target genes | Functions | References |
|----------------------|---------|--------------|-----------|------------|
| **Up-regulated by H/I** |         |              |           |            |
| miR-7-5p             | Rat     | Sirtuin 1    | Enhance cerebral inflammation | Zhao and Wang, 2020 |
| miR-19a-3p           | Human, rat | IGFBP3 | Promote inflammation | Chai et al., 2020 |
| miR-20b              | Rat     | NLRP3        | Promote inflammation by activate NLRP3 signaling | Zhao et al., 2019 |
| miR-21-3p            | Rat     | MAT2B        | Promote inflammation | Li C. et al., 2019 |
| miR-155              | Human, mouse | MatB, DUSP14 | Induce inflammatory mediators expression | Shi et al., 2020a |
| miR-186-5p           | Rat     | CTRP3        | Increase microglia/macrophage polarization | Chen et al., 2021 |
| miR-200b             | Rat     | KLF4         | Induce microglia M1 polarization | Wen et al., 2018 |
| miR-210              | Mouse   | TET2         | Induce macrophage infiltration, microglial activation and inflammation | Huang et al., 2018; Ma Q. et al., 2021 |
| miR-217              | Rat     | SIRT1, MEF2D | Induce neuronal injury and inflammatory response | Rao et al., 2019; Shi L. et al., 2020 |
| miR-449c-5p          | Rat     | STAT6        | Promote microglial inflammation | Zhang et al., 2020b |
| miR-3473b            | Mouse   | SOCS3        | Promote neuroinflammation | Wang X. et al., 2018 |
| **Down-regulated by H/I** |       |              |           |            |
| miR-7a-5p            | Rat     | SNCA         | Inhibit mitochondrial fragmentation and oxidative stress | Kim et al., 2018 |
| miR-17-5p            | Rat     | TXNIP        | Inhibit NLRP3 inflammasome | Chen et al., 2018 |
| miR-26b-5p           | Rat     | Smad1        | Inhibit apoptosis and inflammatory responses | Shangguan et al., 2020 |
| miR-29a              | Rat     | TP53NIP1     | Inhibit NLRP3 inflammasome | Liu X. et al., 2021 |
| miR-34c-5p           | Rat     | NCOA1        | Inhibit inflammatory cytokines and NF-κB signaling | Tu and Hu, 2021 |
| miR-124              | Rat     | CYBB         | Inhibit neuroinflammation and NF-κB signaling | Wu et al., 2020 |
| miR-125b             | Rat     | TP53NIP1     | Inhibit neuroinflammation and apoptosis | Li et al., 2018 |
| miR-140-3p           | Rat     | HIF-1a       | Ameliorate inflammation, oxidative stress and apoptosis | Yi et al., 2020 |
| miR-181c-3p          | Rat     | CXCL1        | Inhibit inflammation in astrocytes | Song et al., 2019 |
| miR-182-5p           | Rat, mouse | TLR4 | Inhibit inflammatory cytokines | Wang J. et al., 2018 |
| miR-199b             | Mouse   | AQP4         | Inhibit neuroinflammation | Zhang et al., 2021 |

(Continued)

### TABLE 3 | (Continued)

| H/I regulated miRNAs | Species | Target genes | Functions | References |
|----------------------|---------|--------------|-----------|------------|
| miR-302a-3p          | Mouse   | STAT1        | Inhibit microglial inflammation | Hu et al., 2021 |
| miR-367-3p           | Mouse   | Gprc5a       | Inhibit neuroinflammation | Tabet et al., 2020 |
| miR-374a-5p          | Rat     | Smad6        | Inhibit pro-inflammatory cytokines and NLRP3 inflammasome | Chen et al., 2020b |
| miR-381              | Rat     | IRF4         | Inhibit inflammatory cytokines | Fang et al., 2021 |
| miR-410              | Human   | PTEN         | Inhibit neuroinflammation | Meng et al., 2021 |
| miR-421-3p           | Mouse   | YTHDF1       | Prevent inflammatory response | Zheng et al., 2020 |
| miR-424              | Human, mouse | CDC25A, CCND1, CDK6 | Inhibit neuronal apoptosis and microglia activation | Zhao et al., 2013 |
| miR-485              | Rat     | AIM2         | Inhibit pyroptosis and inflammation | Liang et al., 2020 |
| miR-532-5p           | Rat     | CXCL1        | Inhibit neuroinflammation and NF-κB signaling | Shi et al., 2021 |
| miR-542-3p           | Mouse   | TLR4         | Inhibit neuroinflammation | Cai et al., 2021 |
| miR-665-3p           | Mouse   | TRIM8        | Inhibit apoptosis and microglial inflammation | Zhang et al., 2020d |
| miR-874-3p           | Human, mouse | CXCL12 | Promote angiogenesis and inhibit inflammation | Xie et al., 2020 |
| miR-1202             | Human   | Rab1a        | Inactivate TLR4/NF-κB-involved inflammatory signaling pathway | Song et al., 2020 |
| let-7c-5p            | Human, mouse | Caspase-3 | Inhibit microglial activation | Ni et al., 2015 |
| let-7i               | Human   | CD86, CXCL8, HMGB1 | Regulate leukocyte activation, recruitment and proliferation | Jickling et al., 2016 |

apoptosis by directly targeting pro-inflammatory cytokine IL-6 (Wang Q. et al., 2015).

The information on H/I muscle miRNAs are still limited at present. Altered miRNAs could significantly affect muscle function and change the status of some muscle diseases by targeting key components in the inflammatory pathways. Therefore, it is needed to further investigate the regulation of muscle miRNAs in H/I condition.

### EFFECTS OF δ-OPIOID RECEPTOR ACTIVATION ON MICRORNA EXPRESSION PROFILES IN DIFFERENT ORGANS UNDER NORMOXIA

δ-Opioid receptor is neuroprotective against H/I injury in the brain (Zhang et al., 2002; Chao et al., 2008, 2009; Kang et al., 2009; He et al., 2013a). The administration of DOR agonists can
TABLE 4 | H/I-induced changes in miRNAs in H/I-insensitive organs with defined target genes.

| Organ            | H/I regulated miRNAs | Species | Target genes | Functions                                                                 | References                                |
|------------------|----------------------|---------|--------------|---------------------------------------------------------------------------|-------------------------------------------|
| Liver            | Up-regulated by H/I  |         |              |                                                                           |                                           |
|                  | miR-210              | Human   | VMP1         | Mediate hypoxia-induced HCC cell metastasis and liver inflammation        | Ying et al., 2011; Song et al., 2014     |
|                  | miR-370              | Mouse   | TGFBR2       | Induce proinflammatory cytokines and hepatic histological damage         | Li et al., 2015                          |
|                  | miR-450b-5p          | Mouse   | CRYAB        | Induce inflammatory cytokines and inhibit macrophage M2 polarization     | Huang et al., 2020                       |
| Down-regulated by H/I | miR-24-3p          | Mouse   | STING        | Inhibit inflammatory response and apoptosis in hepatic I/R process       | Shen et al., 2020                        |
|                  | miR-128-3p           | Mouse   | Rnd3         | Activate NF-κB signaling                                                  | Mou et al., 2020                         |
|                  | miR-140-5p           | Mouse   | CAPN1        | Inhibit inflammatory response and apoptosis                             | Yu et al., 2021                          |
|                  | miR-142-3p           | Mouse   | MARCKS       | Attenuate hepatic I/R injury and inflammation                            | Li Y. et al., 2020                       |
|                  | miR-146a             | Mouse   | IRAK1, TRAF6,TLR4 | Inhibit proinflammatory cytokines release and apoptosis | Jiang et al., 2014; Chungen et al., 2020 |
|                  | miR-148a             | Mouse   | CaMKIIα      | Inhibit TLR4-mediated inflammation                                       | Zheng et al., 2018                       |
| Muscle           | Up-regulated by H/I  |         |              |                                                                           |                                           |
|                  | miR-93               | Mouse   | IRF9         | Induce M2-like macrophage polarization in ischemic muscle                | Hazarika et al., 2013; Ganta et al., 2017|
|                  | miR-155              | Human   | SOCS-1       | Aggravate inflammatory response, leukocyte infiltration and tissue damage| Eisenhardt et al., 2015                  |
| Down-regulated by H/I | miR-92b-3p          | Rat     | HIF1A        | Inhibit inflammatory cytokines                                           | Wang and Quan, 2021                      |
|                  | miR-98               | Human   | IL6          | Modulate inflammation and PASMC apoptosis                                | Wang Q. et al., 2015                     |
|                  | miR-146b             | Mouse   | TRAF6        | Inhibit inflammatory factors expression                                  | Desjarlais et al., 2019                  |
|                  | miR-let-7a           | Human   | STAT3        | Inhibit inflammation                                                     | Cheng et al., 2020                       |

PASMC, pulmonary artery smooth muscle cells.

prolong survival of peripheral organs, such as lung, heart, liver, and kidney (Peart et al., 2005; Patel et al., 2006). As a protective molecule, DOR can tonically regulate miRNA expression even in the normoxic condition. We measured miRNA expression profiles in different organs such as the kidney, heart, brain, and liver after DOR activation with a specific and potent DOR agonist UFP-512 applied in Sprague Dawley rats (Yang et al., 2012; He et al., 2013b; Zhi et al., 2016, 2017). DOR activation can influence the expression of many miRNAs in different organs. As summarized in Table 5, the brain had the most dramatic changes in miRNAs after DOR activation. Conversely, miRNAs in the heart and liver kept relatively stable during the observation (DOR activation for 1, 5, and 10 days), suggesting a differential regulation of miRNAs among organs in response to DOR signals under normoxic condition.

Among hypoxia-sensitive organs, seven common miRNA changes were observed in the kidney and brain, including miR-21, miR-29b, miR-298, miR-347, miR-351, miR-466b, and miR-511 (Table 5; Yang et al., 2012; He et al., 2013b). MicroRNAs in the kidney displayed the similar expression tendency with those of the brain. For instance, miR-29b was significantly down-regulated in the brain and kidney at 1 day after DOR activation with UFP-512 and maintained at a relatively stable level after 5–10 days DOR activation. Reduced expression level of miR-347 was observed after DOR activation at day 1 in the brain, and at days 5 and 10 in the kidney. Similarly, miR-511 was significantly down-regulated after DOR activation in rat brain and kidney at day 10 (Tables 6, 7). In contrast, there were few common miRNA changes among hypoxia-insensitive organ (liver) and hypoxia-sensitive organs. In our work, only the alternation of miR-107-3p expression was seen in both the heart and liver in normoxic condition upon DOR activation (Table 5). Further investigating their functions and elucidating the mechanistic differences between the H/I sensitive and -insensitive organs will yield valuable information for better understand the DOR-mediated regulation of miRNAs in physiological conditions.

TABLE 5 | DOR-activation induced changes in miRNA expression profiles in normoxic condition.

| Organs | Kidney | Brain | Heart | Liver |
|--------|--------|-------|-------|-------|
| miRNAs | mn-7f   | mn-21 | mn-107-3p | mn-107-3p |
|        | mn-20b-5p | mn-29a | mn-128-3p | mn-122-5p |
|        | mn-21   | mn-29b | mn-141-3p | mn-148a-5p |
|        | mn-29b   | mn-31  | mn-350 | mn-152 |
|        | mn-212  | mn-101b | mn-350 | mn-184 |
|        | mn-298  | mn-186 | mn-324-3p | mn-192-5p |
|        | mn-347  | mn-298 | mn-347 | mn-363* |
|        | mn-351  | mn-351 | mn-466b | mn-466b |
|        | mn-511  | mn-511 | mn-511 | mn-511 |

Summarized from our published articles (Yang et al., 2012; He et al., 2013b; Zhi et al., 2016, 2017).
EFFECTS OF δ-OPIOID RECEPTOR ACTIVATION ON MICRORNA EXPRESSION PROFILES IN DIFFERENT ORGANS UNDER HYPOXIA

Since either DOR activation or hypoxic condition has a profound impact on miRNA expression profiles in different organs, it will be interesting to learn the possible effect of DOR activation on hypoxia-induced miRNA changes. Our studies have shown that miRNA expression profiles can be significantly altered when DOR activation was applied to hypoxic organs (Yang et al., 2012; He et al., 2013b; Zhi et al., 2016, 2017). We noticed that the differential alternations in the miRNAs largely depended on the duration of hypoxia, and DOR activation led to diverse outcomes in response to short-term or prolonged hypoxia in different organs.

As one of the hypoxia-sensitive organs, the hypoxic brain showed the most dramatic changes in miRNA expression in response to DOR activation. Some miRNAs were largely
altered at the earliest time point (1 day), including miR-347, miR-101b, miR-466b, miR-29a, miR-363*, and miR-31 (Yang et al., 2012). The majority of miRNAs, especially those that mediate cyto-protective function such as anti-neuroinflammation, were down-regulated compared with those in normal condition. Among them, miR-29a alleviated cerebral ischemia/reperfusion injury via down-regulating target gene TP53INP1 and the NF-κB/NLRP3 pathway (Liu X. et al., 2021). In the brain exposed to a mid-term hypoxia (5 days), DOR activation provoked even more miRNA reduction as compared to that in short-term hypoxia (1 day), whereas the expression of miRNAs turned to the baseline level upon DOR activation under prolonged hypoxia (Table 6; Yang et al., 2012). These findings implicated that brain miRNA expression responded quickly after the hypoxia insult, and possibly involved in anti-hypoxic injury by modulating the expression of target genes.

δ-Opioid receptor activation can also modify hypoxia-induced changes of miRNA expression in the kidney. The changes in several miRNAs could be detected upon DOR activation in the kidney exposed to a continuous hypoxia for a prolonged period. For instance, the down-regulation of miR-511 and miR-298 expression was observed upon DOR activation followed by a continuous exposure to hypoxia for 5 to 10 days (He et al., 2013b). In the case of miR-370, miR-20b-5p, and miR-298a/b, although hypoxia alone did not alter their expression levels at certain time points, the administration of UFP-512 to the hypoxic heart induced a further upregulation in terms of the expression of miR-141-3p, miR-376a-3p and miR-134-5p. Moreover, the expression of miR-134-5p and miR-7b was increased throughout the entire time course after DOR activation under hypoxia, suggesting their important roles in the regulation of renal adaptation to hypoxic stress (Table 7; He et al., 2013b).

Unlike other hypoxia-sensitive organs, the majority of altered miRNAs in the heart was up-regulated under 1 day hypoxia. The administration of UFP-512 to the hypoxic heart induced a further upregulation in terms of the expression of miR-141-3p, miR-376a-3p and miR-134-5p. Moreover, the expression of miR-134-5p and miR-7b was increased throughout the entire time course after DOR activation under hypoxia, suggesting their important roles in the regulation of renal adaptation to hypoxic stress (Table 8; Zhi et al., 2016).

Similar to that in hypoxia-sensitive organs, miRNA expression in hypoxia-insensitive organs can also be influenced by DOR activation in hypoxic condition. The expression of miR-34a-5p, miR-142-5p, miR-145-5p, miR-146a-5p, and miR-204-5p were significantly increased in the liver after DOR activation and hypoxic stress (Zhi et al., 2017). MiR-192-5p was the only miRNA whose expression level started to decrease after DOR activation under hypoxia (Table 9). MiR-146a was reported to ameliorate ischemia/reperfusion injury in vivo and hypoxia/reoxygenation injury in vitro by directly suppressing IRAK1 and TRAF6 in the liver (Jiang et al., 2014). Prolonged hypoxia could down-regulate miR-146a level, whereas DOR activation restored miR-146a expression, which might inhibit pro-inflammatory cytokine release and cellular apoptosis. Therefore, DOR signaling likely functions to upregulate hepatic tolerance to hypoxic stress by differentially modulating the expression of different miRNAs.

Collectively, among hypoxia-sensitive organs, the kidney and brain had a common change in the miRNAs, i.e., a significant

![Table 8](image)

| miRNA          | 1 day |                     | 5 days |                     | 10 days |
|----------------|-------|---------------------|--------|---------------------|---------|
|                | Hypoxia | C + DOR | H + DOR | Hypoxia | C + DOR | H + DOR | Hypoxia | C + DOR | H + DOR |
| miR-7a-5p      | ↑      | –       | –       | –       | –       | –       | –       | –       | –       |
| miR-141-3p     | ↑      | ↑       | ↑       | –       | –       | –       | –       | –       | –       |
| miR-196c-5p    | ↑      | –       | –       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       |
| miR-200a-3p    | ↑      | ↑       | ↑       | –       | –       | –       | –       | –       | –       |
| miR-200b-3p    | –      | ↑       | –       | –       | –       | –       | –       | –       | –       |
| miR-203a-3p    | ↑      | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       |
| miR-324-3p     | ↑      | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       |
| miR-376a-3p    | ↑      | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       |
| miR-135a-5p    | ↑      | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       |
| miR-193a-3p    | ↑      | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       |
| miR-338-3p     | ↑      | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       |
| miR-128-3p     | –      | –       | –       | –       | –       | –       | –       | –       | –       |
| miR-134-5p     | –      | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       |
| miR-350        | –      | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       |
| miR-107-3p     | –      | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       |
| miR-7b         | –      | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       | ↑       |

↑, up-regulation; ↓, down-regulation; –, no statistical difference; C, normoxic control; H, hypoxia; DOR, DOR activation. Comparisons: hypoxia vs. C; C + DOR vs. C; H + DOR vs. H. Summarized from our published article (Zhi et al., 2016).
TABLE 9 | Effects of DOR activation on liver miRNAs in prolonged hypoxia.

| miRNA     | 1 day | 5 days | 10 days |
|-----------|-------|--------|---------|
|           | Hypoxia | C + DOR | H + DOR | Hypoxia | C + DOR | H + DOR | Hypoxia | C + DOR | H + DOR |
| miR-7a-5p | ↑      | –      | –       | –       | –       | –       | –       | –       | –       |
| miR-10a-5p| ↑      | ↑      | ↓       | –       | –       | –       | –       | –       | –       |
| miR-25-3p | ↑      | ↑      | ↑       | –       | –       | –       | –       | –       | –       |
| miR-26b-5p| ↑      | ↓      | ↑       | –       | –       | –       | –       | –       | –       |
| miR-30e-5p| ↑      | –      | –       | –       | –       | –       | –       | –       | –       |
| miR-34a-5p| ↓      | ↑      | ↓       | ↑       | ↓       | ↑       | ↑       | ↓       | ↓       |
| miR-34c-5p| ↑      | –      | ↑       | –       | –       | –       | –       | –       | –       |
| miR-107-3p| ↑      | –      | –       | ↑       | –       | –       | –       | –       | –       |
| miR-122-5p| ↑      | ↓      | ↓       | –       | –       | –       | –       | –       | –       |
| miR-128a-3p| ↑    | –      | ↑       | –       | –       | –       | –       | –       | –       |
| miR-135b-5p| ↑      | –      | –       | –       | –       | –       | –       | –       | –       |
| miR-142-6p| ↑      | –      | ↓       | ↑       | –       | –       | –       | –       | –       |
| miR-145-5p| ↑      | –      | ↑       | ↑       | –       | –       | –       | –       | –       |
| miR-146a-5p| –    | –      | ↑       | –       | –       | –       | –       | –       | –       |
| miR-181a-5p| ↑      | –      | –       | –       | –       | –       | –       | –       | –       |
| miR-182  | ↑      | –      | ↑       | ↓       | ↑       | –       | –       | –       | –       |
| miR-184  | ↓      | ↑      | ↓       | ↑       | ↓       | –       | –       | –       | –       |
| miR-192-5p| ↑      | ↑      | ↓       | ↑       | ↑       | ↓       | ↑       | ↓       | ↓       |
| miR-204-5p| ↑      | ↑      | ↓       | ↑       | ↑       | ↓       | ↑       | ↓       | ↓       |

↑, up-regulation; ↓, down-regulation; –, no statistical difference; C, normoxic control; H, hypoxia; DOR, DOR activation. Comparisons: hypoxia vs. C; C + DOR vs. C; H + DOR vs. H. Cited from our previous work (Zhi et al., 2017).

table alternation in nine miRNAs in both organs (Yang et al., 2012; He et al., 2013b), whereas hypoxia-sensitive and -insensitive organs had no common change at all (Table 10).

It seems that hypoxia comprehensively modifies miRNA profiles with a major difference among organs, while DOR signaling is able to modulate such regulation in most of these organs (Feng et al., 2012; He et al., 2013a; Nallamshetty et al., 2013; Yang et al., 2015). DOR activation may induce cyto-protection against H/I insult in both hypoxia-sensitive and -insensitive organs, at least partially, through modulating miRNA expression.

TABLE 10 | DOR-activation modifies hypoxia-induced changes in miRNA expression.

| Organs          | Kidney | Brain | Heart | Liver |
|-----------------|--------|-------|-------|-------|
| miRNAs          | miR-20b-5p | miR-20b-5p | miR-7b | miR-34a-5p |
|                 | miR-21  | miR-21  | miR-107-3p | miR-142-5p |
|                 | miR-29a | miR-29a | miR-134-5p | miR-145-5p |
|                 | miR-29b | miR-31  | miR-141-3p | miR-146a-5p |
|                 | miR-212 | miR-101b | miR-200b-3p | miR-192-5p |
|                 | miR-298 | miR-186  | miR-376a-3p | miR-204-5p |
|                 | miR-324-3p | miR-212  | –      | –      |
|                 | miR-347 | miR-298  | –      | –      |
|                 | miR-363* | miR-347  | –      | –      |
|                 | miR-370 | miR-351  | –      | –      |
|                 | miR-466b | miR-363* | –      | –      |
|                 | miR-511 | miR-370  | –      | –      |

Summarized from our published articles (Yang et al., 2012; He et al., 2013b; Zhi et al., 2016, 2017).

CONCLUSION AND PHARMACOLOGICAL PERSPECTIVES

Hypoxic/ischemic-induced inflammatory injury to different organs is a frequently encountered clinical problem and the common cause of various diseases with limited therapeutic options. Because the role of miRNAs in controlling H/I inflammation, recent studies on miRNA expression under H/I condition have drawn much attention from clinicians and scientists worldwide. Many experiments have been conducted in cell models, animal models, and patients to investigate the potential targets and signaling pathways of miRNAs involved in H/I pathology. Some of the miRNAs are regarded as injury factors under hypoxic condition by promoting cellular inflammation, mitochondrial dysfunction, oxidative stress and apoptosis, while others play protective roles against H/I insult by inhibiting pro-inflammatory cytokines release and NLRP3 inflammasome (Tables 1–4). Our summary of increased or decreased miRNAs in response to DOR activation (Tables 5, 10) provides a guide for future clarifications of their functions in controlling H/I inflammation.

Hypoxic/ischemic stress comprehensively alters miRNA expression in H/I-sensitive and -insensitive organs, largely depending on the duration of hypoxia. MicroRNA expression in H/I-sensitive organs such as brain and kidney often respond quickly to relatively short-term hypoxia (1 day). After prolonged
hypoxia (10 days), the expression of some miRNAs turned back to the baseline level. There is evidence suggesting that a mild/moderate H/I stress may induce pro-inflammatory cytokine release and causes a quick inflammatory response, whereas a severe/prolonged stress eventually causes cell apoptosis and necrosis (Krock et al., 2011; Hadijapanayi and Schilling, 2013). The differential cellular signaling is partially mediated by the miRNA-induced repression of gene expression.

Although various miRNAs can exhibit very different responses even in the same organ under similar H/I condition, there are several H/I sensitive miRNAs that display common changes among different organs. These miRNAs were named “hypoxamirRs”, including miR-21, miR-210, and miR-199a (Nallamshetty et al., 2013; Greco et al., 2014; Azzouzi et al., 2015; Bertero et al., 2017). Accumulating evidence shows that the expression of miR-21 can be directly induced by hypoxia stimulation in several cell types due to the consensus hypoxia-response-element (HRE) sequence in its promoter region (Kulshreshtha et al., 2007; Parikh et al., 2012). Similarly, the expression of miR-210 could be up-regulated by either HIF-dependent mechanism via HRE binding (Lee et al., 2009; Pocock, 2011), or HIF-independent transcriptional regulations (Bertero et al., 2017). One of the most important functions mediated by these “hypoxamirRs” is cellular inflammation (Tables 1–4).

Aging is a key factor affecting H/I inflammation and miRNA expression. In contrast to the immature and young organs, the aged ones are more sensitive to H/I stress. The oxygen-deprived conditions (hypoxia and ischemia) lead to oxidative stress, cellular damage and protein modifications (Adav and Sze, 2020). H/I inflammation and abnormal miRNA expression have been proposed as risk factors for aging and neurodegenerative diseases. Some circulating inflamma-miRs, e.g., miR-21-5p and miR-126-3p, are even thought as potential biomarkers of cognitive impairment AD patients (Giuliani et al., 2021). MicroRNAs implicated in pathological aging such as miR-92a-5p and miR-532-5p are also regarded as potential biomarkers and putative molecular effectors of cognitive frailty (Carini et al., 2021). Serum miR-214 as well as salivary miR-874 and miR-145-3p might serve as auxiliary biomarkers for PD (Chen et al., 2020d; Li L., et al., 2021). In aged rats, transcription factor HIF could protect against ischemic brain injury by reducing inflammatory responses via the Akt signaling pathway (Du et al., 2020). All these facts suggest that an elevated level of inflammation exists in various aging-related chronic diseases, and modulating miRNA expression is a promising avenue for the prevention and treatment of aging and chronic diseases.

The miRNA expression can be modulated by sequence-specific miRNA mimics (or agomirs) and inhibitors (or antagonimirs), both in vitro and in vivo. A recent study showed that miR-363-3p treatment attenuates brain ischemia-induced long-term cognitive deficits in rats (Panta et al., 2020), suggesting the potential applications of miRNA mimics. The process of miRNA biogenesis involves transcription, pre-miRNA splicing, exporting, and stability of mature miRNAs. Therefore, the miRNA expression can be modulated by specific molecular signals.

The information in this review suggests that DOR activation is effective in protecting organs against H/I injury, with the capability of modulating miRNAome in both normoxic and hypoxic conditions. Although the direct regulatory mode of DOR on miRNA expression is still unknown, DOR signaling may affect miRNA biogenesis by modulating some key transcriptional factors. For instance, ERK is found to suppress pre-miRNA export from the nucleus to cytoplasm through phosphorylation of Exportin-5, resulting in a global reduction of pre-miRNA loading and miRNA synthesis (Xie et al., 2020; Zhang et al., 2020d). Since ERK activity could be upregulated by DOR activation (Ma et al., 2005; Cai et al., 2021), DOR may regulate miRNA expressions via this signaling pathway.

Different kinds of DOR agonists have been developed in the past. Many of them displayed analgesic, antidepressant, anxiolytic and other opioid effects. For instance, Deltorphin I is an opioid peptide with relatively high affinity and selectivity to DOR and produce centrally mediated analgesic effects in animals (Thomas et al., 1997). Another commonly used one is delta opioid peptide DADLE ([D-Ala2, D-Leu5]-Enkephalin), which was used for pre-conditioning and post-conditioning to induce neuroprotection against hippocampal injury resulted from transient forebrain ischemia in rats (Wang S. et al., 2011). There are also other non-peptide DOR agonists used for antidepressant, anxiolytic or anti-inflammatory properties, including SNC-80 (Bilsky et al., 1995; Perrine et al., 2006), AZD2327 (Hudzik et al., 2014), and ADL5859 (Nozaki et al., 2012). In addition, AR-M 100390 (Wei et al., 2000) and DPI-3290 (Ananthan, 2006) were also used for DOR agonists. However, UFP-512 that we commonly used in our studies might yield more reliable data for DOR activation because of its specificity and potent binding affinity (Balboni et al., 2002; He et al., 2013b; Xia, 2015). Future development of more specific DOR agonists with lower side-effects may facilitate the application of DOR for the treatment of H/I inflammation.

In summary, it is possible to develop a new protective strategy against H/I injury by activating DOR signaling and targeting certain miRNAs to suppress H/I inflammation in both hypoxia/ischemia-sensitive and -insensitive organs. However, controversies and ambiguity still persist in the literature, especially regarding the up-regulation versus down-regulation of miRNAs under different conditions and their downstream targets in the different organs. Moreover, the molecular mechanisms involved in the DOR-mediated regulation of miRNAs are largely unknown at present. The controversies may be partially attributed to the differences in the models, species, and experimental approaches among different studies. Nevertheless, the solution of the above-mentioned fundamental issues depends on more reliable and in-depth studies in future.

**AUTHOR CONTRIBUTIONS**

YC initiated the project and made the outline. YC searched the literature and prepare the manuscript. YH, SZ, and XH participated in writing the manuscript. YX and DX supervised the project and revised the manuscript. All authors contributed to the article and approved the submitted version.
FUNDING

This work was supported by the National Natural Science Foundation of China (81873361), Science and Technology Commission of Shanghai Municipality (18401970100), Natural Science Foundation of Jiangsu Province (BK20200180 and BK202111064), and Changzhou Science and Technology Program (CJ202000089 and CJ20200106).

REFERENCES

Adav, S. S., and Sze, S. K. (2020). Hypoxia-Induced Degenerative Protein Modifications Associated with Aging and Age-Associated Disorders. Aging Dis. 11, 341–364. doi: 10.10343/A3D.2019.0604
Ananthan, S. (2006). Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. AAPS J. 8, E118–E125. doi: 10.1208/s00032-006-0011-6
Azouzi, H. E., Leptidis, S., Dovendans, P. A., and De Windt, L. J. (2015). Impact of MicroRNAs Bellinger, M. A., Bean, J. S., Rader, M. A., Heinz-Taheny, K. M., Nunes, J. S., and Ananthan, S. (2006). Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. AAPS J. 8, E118–E125. doi: 10.1208/s00032-006-0011-6
Bai, M., Chen, H., Ding, D., Song, R., Lin, J., Zhang, Y., et al. (2019). MicroRNA-214 promotes chronic kidney disease by disrupting mitochondrial oxidative phosphorylation. Kidney Int. 95, 1389–1404. doi: 10.1016/j.kint.2018.12.028
Balboni, G., Salvadori, S., Guerrini, R., Negrli, L., Giannini, E., Jinsmaa, Y., et al. (2002). Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J. Med. Chem. 45, 5556–5563. doi: 10.1021/jm010336e
Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233. doi: 10.1016/j.cell.2009.01.002
Bellinger, M. A., Bean, J. S., Rader, M. A., Heinz-Taheny, K. M., Nunes, J. S., and Ananthan, S. (2006). Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. AAPS J. 8, E118–E125. doi: 10.1208/s00032-006-0011-6
Chao, D., Balboni, G., Lazarus, L. H., Salvadori, S., and Xia, Y. (2008). Activation and Worsened Renal Ischemia/Reperfusion Injury. Kidney Int. 73, 1389–1404. doi: 10.1016/j.kint.2008.05.003
Chao, D., He, X., Yang, Y., Bazzy-Asaad, A., Lazarus, L. H., Balboni, G., et al. (2012). OR activation inhibits anoxic/ischemic Na+ influx through Na+ channels via PKC mechanisms in the cortex. Exp. Neurol. 236, 228–239. doi: 10.1016/j.expneurol.2012.05.006
Chao, D., and Xia, Y. (2010). Ionic storm in hypoxic/ischemic stress: can opioid receptors substitute it? Prog. Neurobiol. 90, 439–470. doi: 10.1016/j.pneurobiol.2009.12.007
Chen, D., Dixon, B. J., Doycheva, D. M., Li, B., Zhang, Y., Hu, Q., et al. (2018). IRE1alpha inhibition decreased TXNIP/NLRP3 inflammasome activation through miR-17-5p after neonatal hypoxic-ischemic brain injury in rats. J. Neuroinflammation 15:32. doi: 10.1186/s12974-018-1077-9
Chen, J., Zhang, M., Zhang, S., Wu, J., and Xue, S. (2020a). Rno-microRNA-30c promotes myocardial ischemia reperfusion injury in rats through activating NF-κB pathway and targeting SIRT1. BMC Cardiovasc. Disord. 20:240. doi: 10.1186/s12872-020-01520-2
Chen, Y., Han, X., Sun, Y., He, X., and Xue, D. (2020b). A circulating exosomal microRNA panel as a novel biomarker for monitoring post-transplant renal graft function. J. Cell. Mol. Med. 24, 12154–12163.
Chen, Y., He, X., Wang, S., and Xia, Y. (2020c). delta-Opioid Receptors, microRNAs, and Neuroinflammation in Cerebral Ischemia/Hypoxia. Front. Immunol. 11:421. doi: 10.3389/fimmu.2020.00421
Chen, Y., Zheng, J., Su, L., Chen, F., Zhu, R., Chen, X., et al. (2020d). Increased Salivary microRNAs That Regulate DJ-1 Gene Expression as Potential Markers for Parkinson’s Disease. Front. Aging Neurosci. 12:210. doi: 10.3389/fnagi.2020.00210
Chen, Z., Hu, Y., Lu, R., Ge, M., and Zhang, L. (2020e). MicroRNA-374a-5p inhibits neuroinflammation in neonatal hypoxic-ischemic encephalopathy via regulating NLRP3 inflammasome targeted Smad6. Life Sci. 252:117664. doi: 10.1016/j.lfs.2020.117664
Chen, Y., He, X., Sun, Q., Pan, H., Huang, P., Ding, J., et al. (2017). MicroRNA-4639 is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson’s disease. Front. Aging Neurosci. 9:232. doi: 10.3389/fnagi.2017.00232
Chen, Y., Liu, W., Chen, M., Sun, Q., Chen, H., and Li, Y. (2021). Up-regulating IncRNA OIP5-AS1 protects neuron injury against cerebral hypoxia-ischemia induced inflammation and oxidative stress in microglia/macrophage through activating CTRP3 via sponging miR-186-5p. Int. Immunopharmacol. 92:10733. doi: 10.1016/j.intimp.2020.107339
Chen, Y., Shi, J., Xia, T. C., Xu, R., He, X., and Xia, Y. (2019). Preservation Solutions for Kidney Transplantation: history, Advances and Mechanisms. Cell Transplant. 28, 1472–1489. doi: 10.1080/0963689719872699
Cheng, G., He, L., and Zhang, Y. (2020). LncRNA-Cox2 promotes pulmonary arterial hypertension by regulating the let-7a-mediated STAT3 signaling pathway. Mol. Cell. Biochem. 475, 239–247. doi: 10.1007/s11010-020-08377-6
Cheng, N., Li, L., Wu, Y., Wang, M., Yang, M., Wei, S., et al. (2021). microRNA-30e up-regulation alleviates myocardial ischemia-reperfusion injury and promotes ventricular remodeling via SOX9 repression. Mol. Immunol. 130, 96–103. doi: 10.1016/j.molimm.2020.11.009
Chung, Y., Dongfang, Z., and Guoyuan, X. (2020). MicroRNA-146a Protects Against Ischemia/Reperfusion Liver Injury Through Inhibition of Toll-like Receptor 4 Signaling Pathway in Rats. Transplant. Proc. 52, 1007–1013. doi: 10.1016/j.transproceed.2020.01.046
Desjarlais, M., Dussault, S., Rivard, F., Harel, S., Sanchez, V., Hussain, S. N. S., et al. (2019). Forced expression of microRNA-146b decreases TRAF6-dependent inflammation and improves ischemia-induced neovascularization in hypercholesterolemic conditions. Atherosclerosis 289, 73–84. doi: 10.1016/j.atherosclerosis.2019.08.010
Ding, C., Zheng, J., Wang, B., Li, Y., Xiang, H., Dou, M., et al. (2020). Exosomal MicroRNA-374b-5p From Tubular Epithelial Cells Promoted M1 Macrophages Activation and Worsened Renal Ischemia/Reperfusion Injury. Front. Cell Dev. Biol. 8:57693. doi: 10.3389/fcell.2020.587693
Dirksen, M. T., Laarman, G. J., Simoons, M. L., and Duncker, D. J. (2007). Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc. Res. 74, 343–355. doi: 10.1016/j.cardiores.2007.01.014

Frontiers in Aging Neuroscience | www.frontiersin.org
May 2022 | Volume 14 | Article 847374
Ma, Q., Dasgupta, C., Shen, G., Li, Y., and Zhang, L. (2021). MicroRNA-210

Lorenzen, J. M., Kaucsar, T., Schauerte, C., Schmitt, R., Rong, S., Hubner, A., et al. (2015). Hypoxia promotes liver-stage malaria infection in primary human hepatocytes in vitro. *Dis. Model Mech.* 7, 215–224. doi: 10.1242/dmm.013490

Ni, J., Wang, X., Chen, S., Liu, H., Wang, Y., Xu, X., et al. (2015). MicroRNA-let-7c-5p protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia activation. *Brain Behav. Immun.* 49, 75–85. doi: 10.1016/j.bbi.2015.04.014

Nozaki, C., Le Bourdonnec, B., Reiss, D., Windt, R. T., Little, P. J., Dolle, R. E., et al. (2012). delta-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization. *J. Pharmacol. Exp. Ther.* 342, 799–807. doi: 10.1124/jpet.111.188987

Panta, A., Montgomery, K., Nicolas, M., Mani, K. K., Sampath, D., and Sohrabji, F. (2020). MicroRNA-125b-3p ancient micro RNAs in pathological and physiological settings. *Vascul. Pharmacol.* 115, 1–12. doi: 10.1016/j.vph.2020.101671

Peart, J. N., Gross, E. R., and Gross, G. J. (2005). Opioid-induced preconditioning: role of caveolar microdomains and delta-opioid receptors. *Am. J. Physiol. Heart Circ. Physiol.* 291, H344–H350. doi: 10.1152/ajpheart.01100.2005

Perrine, S. A., Hoshaw, B. A., and Unterwald, E. M. (2006). Delta opioid receptor ligands modulate anxiety-like behaviors in the rat. *Br. J. Pharmacol.* 147, 864–872. doi: 10.1038/sj.bjp.0706686

Pocock, R. (2011). Invited review: decoding the microRNA response to hypoxia. *Pharmacol. Res.* 63, 307–315. doi: 10.1016/j.phrs.2010.09.010

Pushapakumar, S., Kundu, S., Weber, G., and Sen, U. (2011). Exogenous hydrogen sulfide and microRNA-21 antagonism attenuates macrophage-mediated inflammation in ischemia reperfusion injury of the aged kidney. *Geroscience* 35, 1349–1367. doi: 10.1007/s11357-020-00299-6

Qu, Y., Zhang, J., Zhang, J., and Xiao, W. (2021). MiR-708-3p Alleviates Inflammation and Myocardial Injury After Myocardial Infarction by Inhibiting ADAM17 Expression. *Inflammation* 44, 1083–1095. doi: 10.1007/s10753-020-01404-9

Rao, G., Zhang, W., and Song, S. (2019). MicroRNA217 inhibition relieves cerebral ischemia/reperfusion injury by targeting SIRT1. *Mol. Med. Rep.* 20, 1221–1229. doi: 10.3892/mmr.2019.10317

Shangguan, Y., Han, J., and Su, H. (2020). GASS knockdown ameliorates apoptosis and inflammatory response by modulating miR-26b-5p/Smad1 axis in cerebral ischemia/reperfusion injury. *Behav. Brain Res.* 379,112370. doi: 10.1016/j.bbr.2019.112370

Shapiro, M. D., Bagley, J., Latz, J., Godwin, J. G., Ge, X., Tullius, S. G., et al. (2011). MicroRNA expression data reveals a signature of kidney damage following ischemia reperfusion injury. *PloS One* 6:e23011. doi: 10.1371/journal.pone.0023011

Shen, A., Zheng, D., Luo, Y., Mou, T., Chen, Q., Huang, Z., et al. (2020). MicroRNA-24-3p alleviates hepatic ischemia and reperfusion injury in mice through the repression of STING signaling. *Biochem. Biophys. Res. Commun.* 522, 47–52. doi: 10.1016/j.bbrc.2019.10.182

Meng, Q., Yang, P., and Lu, Y. (2021). MicroRNA-410 serves as a candidate biomarker in hypoxic-ischemic encephalopathy newborns and provides neuroprotection in oxygen-glucose deprivation-injured PC12 and SH-SYSY cells. *Brain Behav.* 11:e2293. doi: 10.1002/brb3.2293

Mou, T., Luo, Y., Huang, Z., Zheng, D., Pu, X., Shen, A., et al. (2020). Inhibition of microRNA-128-3p alleviates liver ischemia-reperfusion injury in mice through repressing the Rnd3/NF-kappaB axis. *Innate Immun.* 26, 528–536. doi: 10.1177/175343920928449

Nallamshetty, S., Chan, S. Y., and Loscalzo, J. (2013). Hypoxia: a master regulator of microRNA biogenesis and activity. *Free Radic. Biol. Med.* 64, 20–30. doi: 10.1016/j.freeradbiomed.2013.05.022

Nangaku, M., and Eckardt, K. U. (2007). Hypoxia and the HIF system in kidney disease. *J. Mol. Med.* 85, 1325–1330. doi: 10.1007/s00109-007-0278-y

Ng, S., March, S., Galstian, A., Hanson, K., Carvalho, T., Mota, M. M., et al. (2014). Hypoxia promotes liver-stage malaria infection in primary human hepatocytes in vitro. *Dis. Model Mech.* 7, 215–224. doi: 10.1242/dmm.013490

Ni, J., Wang, X., Chen, S., Liu, H., Wang, Y., Xu, X., et al. (2015). MicroRNA-let-7c-5p protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia activation. *Brain Behav. Immun.* 49, 75–85. doi: 10.1016/j.bbi.2015.04.014

Nozaki, C., Le Bourdonnec, B., Reiss, D., Windt, R. T., Little, P. J., Dolle, R. E., et al. (2012). delta-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization. *J. Pharmacol. Exp. Ther.* 342, 799–807. doi: 10.1124/jpet.111.188987

Parikh, V. N., Jin, R. C., Rabello, S., Gulbahce, N., White, K., Hale, A., et al. (2012). MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. *Circulation* 125, 1520–1532. doi: 10.1161/CIRCULATIONAHA.111.062069

Patel, H. H., Head, B. P., Petersen, H. N., Niesman, I. R., Huang, D., Gross, J. G., et al. (2006). Protection of adult rat cardiac myocytes from ischemic cell death: role of caveolar microdomains and delta-opioid receptors. *Am. J. Physiol. Heart Circ. Physiol.* 291, H344–H350. doi: 10.1152/ajpheart.01100.2005

Pearl, J. N., Gross, E. R., and Gross, G. J. (2005). Opioid-induced preconditioning: recent advances and future perspectives. *Vascul. Pharmacol.* 42, 211–218. doi: 10.1016/vph.2005.02.003

Perrine, S. A., Hoshaw, B. A., and Unterwald, E. M. (2006). Delta opioid receptor ligands modulate anxiety-like behaviors in the rat. *Br. J. Pharmacol.* 147, 864–872. doi: 10.1038/sj.bjp.0706686
Shen, Y., Zhao, Y., Wang, L., Zhang, W., Liu, C., and Yin, A. (2018). MicroRNA-194 overexpression protects against hypoxia/reperfusion-induced HK-2 cell injury through direct targeting Rho. J. Cell. Biochem. doi: 10.1002/jcb.28114 [Epub Online ahead of print]

Shi, L., Tian, Z., Fu, Q., Li, H., Zhang, L., Tian, L., et al. (2020). miR-217-regulated MEF2D-HDAC5/NDE6 signaling pathway participates in the oxidative stress and inflammatory response after cerebral ischemia. Brain Res. 1739:146835. doi: 10.1016/j.brainres.2020.146835

Shi, Y., Li, K., Xu, K., and Liu, Q. H. (2020). MiR-155-5p accelerates cerebral ischemia-reperfusion injury via targeting DUSP14 by regulating NF-kappaB and MAPKs signaling pathways. Eur. Rev. Med. Pharmacol. Sci. 24, 1408–1419. doi: 10.26355/eurev_202002_20198

Shi, Y., Yi, Z., Zhao, P., Xu, Y., and Pan, P. (2021). MicroRNA-532-5p protects against cerebral ischemia-reperfusion injury by directly targeting CXCL1. Aging 13, 11528–11541. doi: 10.18632/aging.202846

Sikora, E., Bielak-Zmijewska, A., Duďkowska, M., Krzyżaniski, A., Mosieniak, G., Wieserska, M., et al. (2021). Cellular Senescence in Brain Aging. Front. Aging Neurosci. 13:646924. doi: 10.3389/fnagi.2021.646924

Song, G., Jia, H., Xu, H., Liu, W., Zhi, L., Li, S., et al. (2019). Overexpression of miR-335 reduces myocardial injury following myocardial infarction via regulating target gene IRAK-1. Int. J. Clin. Exp. Pathol. 12, 4560–4570. doi: 10.26355/eurrev_202006_21526

Song, H., Yang, L., Wang, Y., Hao, X., Liu, Z., et al. (2021). Upregulation of miR-194 induces cardiomyocyte apoptosis and inflammation via targeting TRPV3. Braz. J. Med. Biol. Res. 54:e10550. doi: 10.1590/1414-431X202010550

Song, L., Li, L., Xiao, L., Lin, L., and Wei, J. (2021). MiR-23a Is Involved in Myocardial Ischemia/Reperfusion Injury by Directly Targeting CX43 and Regulating Mitophagy. Inflammation 44, 1581–1591. doi: 10.1007/s11910-021-01443-w

Wang, F., and Quan, Q. (2021). Anti-inflammatory role and mechanism of microRNA-92b-3p in the progression of hypoxic pulmonary hypertension. Life Sci. doi: 10.1016/j.lfs.2021.117975 [Epub Online ahead of print]

Wang, J., Jiao, J., Li, Q., Long, B., Wang, K., Liu, J., et al. (2011). miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein 1. Nat. Med. 17, 71–78. doi: 10.1038/nm.2282

Wang, S., Duan, Y., Su, D., Li, W., Tan, J., Yang, D., et al. (2011). Delta opioid peptide [D-Ala2, D-Leu5] enkephalin (DADLE) triggers postconditioning against transient forebrain ischemia. Eur. J. Pharmacol. 658, 140–144. doi: 10.1016/j.ejphar.2011.02.006

Wang, J., Xu, Z., Chen, X., Li, Y., Chen, C., Wang, C., et al. (2018). MicroRNA-182-5p attenuates cerebral ischemia-reperfusion injury by targeting Toll-like receptor 4. Biochem. Biophys. Res. Commun. 505, 677–684. doi: 10.1016/j.bbrc.2018.09.165

Wang, X., Chen, S., Ni, J., Cheng, J., Jia, J., and Zhen, X. (2018). microRNA-3473b contributes to neuroinflammation following cerebral ischemia. Cell Death Dis. 9:11. doi: 10.1038/s41419-017-0014-7

Wang, K., Liu, C., Zhang, X., Feng, C., Zou, L., Zhao, Y., et al. (2015). miR-361-regulated prohibitin inhibits mitochondrial fission and apoptosis and protects heart from ischemia injury. Cell Death Differ. 22, 1058–1068. doi: 10.1038/cdd.2014.200

Wang, Q., Shen, C., Su, J., and Li, X. (2015). A crosstalk triggered by hypoxia and maintained by MCP-1/miR-98/IL-6/p38 regulatory loop between human aortic smooth muscle cells and macrophages leads to aortic smooth muscle cells apoptosis via Stat1 activation. Int. J. Clin. Exp. Pathol. 8, 2670–2679

Wang, S., Ge, L., Zhang, D., Wang, L., Liu, H., Ye, X., et al. (2020). MiR-181c-5p Promotes Inflammatory Response during Hypoxia/Reoxygenation Injury by Downregulating Protein Tyrosine Phosphatase Nonreceptor Type 4 in H9C2 Cardiomyocytes. Oxid. Med. Cell. Longev. 2020:6960941. doi: 10.1155/2020/6960941

Wang, Y., Wang, S., and Wang, J. (2019). miR27a suppresses TLR4-induced renal ischemiareperfusion injury. Mol. Med. Rep. 20, 967–976. doi: 10.3892/mmr.2019.10333

Wang, Z., Zou, K., Sun, Y., Chen, C., and Xue, D. (2020). Let-7c-5p is involved in chronic kidney disease by targeting TGF-β signaling. Bioimed Res. Int. 2020:9690941. doi: 10.1155/2020/9690941

Wei, Z., Brown, W., Takasaki, B., Plobeck, N., Delorme, D., Zhou, F., et al. (2000). N,N-Diethyl-4-(phenylperidin-4-ylidenemethyl)benzamido: a novel, exceptionally potent, delta opioid receptor agonist with oral bioavailability and its analogues. J. Med. Chem. 43, 3895–3905. doi: 10.1021/jm000229p

Wen, M., Li, J., Yang, H., Huang, L., Yang, J., and Wang, X. (2018). Hypertonic saline regulates microglial M2 polarization via miR-200b/KLF4 in cerebral edema treatment. Biochem. Biophys. Res. Commun. 499, 345–353. doi: 10.1016/j.jbrc.2018.03.161

Wu, C., and Huang, C. (2020). MicroRNA-147 inhibits myocardial inflammation and apoptosis following myocardial infarction via targeting HIPK2. Eur. Rev. Med. Pharmacol. Sci. 24, 6279–6287. doi: 10.26355/eurev_202006_21526

Wu, H., Huang, T., Ying, L., Han, C., Li, D., Xu, Y., et al. (2016). MiR-155 is Involved in Renal Ischemia-Reperfusion Injury by Direct Targeting of FoxO3a and Regulating Renal Tubular Cell Pyroptosis. Cell. Physiol. Biochem. 40, 1692–1705. doi: 10.1007/s00973-016-3206-x

Xia, Y. (2015). Neural Functions Of The Delta-Opioid Receptor. Heidelberg: Springer.
Xie, K., Cai, Y., Yang, P., Du, F., and Wu, K. (2020). Upregulating microRNA-874-3p inhibits CXCL12 expression to promote angiogenesis and suppress inflammatory response in ischemic stroke. Am. J. Physiol. Cell Physiol. 319, C579–C588. doi: 10.1152/ajpcell.00001.2020

Xu, Y., Jiang, W., Zhong, L., Li, H., Bai, L., Chen, X., et al. (2020a). miR-195-5p alleviates acute kidney injury through repression of inflammation and oxidative stress by targeting vascular endothelial growth factor. Aging 12, 10235–10245. doi: 10.18632/aging.103160

Xu, Y., Niu, Y., Li, H., and Pan, G. (2020b). Downregulation of lncRNA TUG1 attenuates inflammation and apoptosis of renal tubular epithelial cell induced by ischemia-reperfusion by sponging miR-449-5p via targeting HMGB1 and MMP2. Inflammation 43, 1362–1374. doi: 10.1007/s10753-020-01214-z

Xue, Y., Yang, Y., Zhang, L., Fan, P., Lin, C., Lu, Y., et al. (2021). USP7, negatively regulated by miR-409-5p, aggravates hypoxia-induced cardiomyocyte injury. APMIS 129, 152–162. doi: 10.1111/apm.13100

Xue, Y., Nie, D., Wang, L., Qiu, H., Ma, L., Dong, M., et al. (2021). Microglial Polarization: novel Therapeutic Strategy against Ischemic Stroke. Aging Dis. 12, 466–479. doi: 10.14336/AD.2020.0701

Yang, B., Dong, R., and Zhao, H. (2020). Inhibition of microRNA-346 inhibits myocardial inflammation and apoptosis after myocardial infarction via targeting NFIB. Eur. Rev. Med. Pharmacol. Sci. 24, 11752–11760. doi: 10.26355/eurrev_2020011_23827

Yang, Y., Sandhu, H. K., Zhi, F., Hua, F., Wu, M., and Xia, Y. (2015). Effects of hypoxia and ischemia on microRNAs in the brain. Curr. Med. Chem. 22, 1292–1301.

Yang, Y., Yang, J., Liu, X., Ding, J., Li, S., Guo, X., et al. (2018). Down-regulation of miR-327 Alleviates Ischemia/Reperfusion-Induced Myocardial Damage by Targeting RP105. Cell. Physiol. Biochem. 49, 1049–1063. doi: 10.1159/000493288

Yang, Y., Zhi, F., He, X., Moore, M. L., Kang, X., Chao, D., et al. (2012). delta-opioid receptor activation and microRNA expression of the rat cortex in hypoxia. PLoS One 7, e51524. doi: 10.1371/journal.pone.0051524

Yi, M., Li, Y., Wang, D., Zhang, Q., Yang, L., and Yang, C. (2020). KCNQ1OT1 Exacerbates Ischemia-Reperfusion Injury Through Inhibited Targeting of miRNA-140-3P. Inflammation 43, 1832–1845. doi: 10.1007/s10753-020-01257-z

Yang, Q., Liang, L., Guo, W., Zha, R., Tian, Q., Huang, S., et al. (2011). Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology 54, 2064–2075. doi: 10.1002/hep.24614

Yu, Q., Chen, S., Tang, H., Yang, H., Zhang, J., Shi, X., et al. (2021). miR1405p alleviates mouse liver ischemia/reperfusion injury by targeting CAPN1. Mol. Med. Rep. 24, 675. doi: 10.3892/mmr.2021.12314

Zhang, G., Li, T., Chang, X., and Xing, J. (2021). Long Noncoding RNA SNHG14 Promotes Ischemic Brain Injury Via Regulating miR-199b/AQP4 Axis. Neurochem. Res. 46, 1280–1290. doi: 10.1007/s11064-021-03265-6

Zhang, J., Gibney, G. T., Zhao, P., and Xia, Y. (2002). Neuroprotective role of delta-, but not mu- and kappa-, opioid receptors in cortical neurons. Am. J. Physiol. Cell Physiol. 282, C1225–C1234. doi: 10.1152/ajpcell.00226.2001

Zhang, S., Sun, W., Liang, Z., Yin, X., Ji, Z., Chen, X., et al. (2020b). LncRNA SNHG4 Attenuates Inflammatory Responses by Sponging miR-449c-5p and Targeting vacuole membrane protein 1 in hepatocellular carcinoma. Mol. Cell. Probes 54:101653. doi: 10.1016/j.mcp.2020.101653

Zhang, X., Yang, Y., Li, J., Zheng, L., Shao, Y., Zhu, F., et al. (2020d). MicroRNA-665-3p attenuates oxygen-glucose deprivation-evoked microglial cell apoptosis and inflammatory response by inhibiting NF-kappaB signaling via targeting TRIM8. Int. Immunopharmacol. 85, 106650. doi: 10.1016/j.intimp.2020.106650

Zhang, H., Alam, A., Soo, A. P., George, A. J. T., and Ma, D. (2016). Ischemia-Reperfusion Injury Reduces Long Term Renal Graft Survival: mechanism and Beyond. EBioMedicine 28, 31–42. doi: 10.1016/j.ebiom.2018.01.025

Zhao, H., Wang, J., Gao, L., Wang, R., Liu, X., Gao, Z., et al. (2013). MiRNA-424 protects against permanent focal cerebral ischemia injury in mice involving suppressing microglia activation. Stroke 44, 1706–1713. doi: 10.1161/STROKEAHA.111.005054

Zhao, J., and Wang, B. (2020). MiR-7-5p Enhances Cerebral Ischemia-Reperfusion Injury by Degrading sirt1 mRNA. J. Cardiovasc. Pharmacol. 72, 227–236. doi: 10.1097/FJC.0000000000000852

Zhao, J., Wang, H., Dong, L., Sun, S., and Li, L. (2019). miRNA-20b inhibits cerebral ischemia-induced inflammation through targeting LPR3. Int. J. Mol. Med. 43, 1167–1178. doi: 10.3892/imjmm.2018.4043

Zheng, D., Li, Z., Wei, X., Liu, R., Shen, A., He, D., et al. (2018). Role of miR-148a in Mitigating Hepatic Ischemia-Reperfusion Injury by Repressing the TLR4 Signaling Pathway via Targeting CaMKIIalpha in Vivo and in Vitro. Cell. Physiol. Biochem. 49, 2060–2072. doi: 10.1159/000493716

Zhu, H., Xue, H., Jin, Q., Guo, J., and Chen, Y. (2017). MiR-138 protects cardiac cells against hypoxia through modulation of glucose metabolism by targetting pyruvate dehydrogenase kinase 1. Biosci. Rep. 37:BSR20170296. doi: 10.1042/BSR20170296

Zhu, P., Hamlish, N. X., Thakkar, A. V., Stebeck, A. W. T., Rendell, E. J., Khan, N. H., et al. (2022). BMAL1 drives muscle repair through control of hypoxic NAD(+) regeneration in satellite cells. Genes Dev. 36, 149–166. doi: 10.1101/gad.109606.121

Zou, J., Wu, X., Shi, B., Sun, Y., Qin, F., and Yang, Y. (2020). Inhibition of microRNA-184 reduces H2O2-mediated cardiomyocyte injury via targeting FBXO28. Eur. Rev. Med. Pharmacol. Sci. 24, 11251–11258. doi: 10.26355/eurrev_202011_23614

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chen, He, Zhao, He, Xue and Xia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
